Clinical profile and outcome of newborns who underwent double volume exchange transfusion in the neonatal intensive care unit at B.P. Koirala Institute of Health Sciences, Nepal

*Piush Kanodia¹, Sunil Kumar Yadav¹, Nisha Keshary Bhatta¹, Rupa Rajbhandari Singh¹, Shankar Prasad Yadav¹

Sri Lanka Journal of Child Health, 2016; 45(4): 267-270

Abstract

Introduction: About 50% term and 80% preterm babies develop neonatal jaundice. Treatment to prevent bilirubin encephalopathy consists of phototherapy or exchange transfusion (ET). ET is not risk free, and mortality rates vary from 0.5 to 3.3%.

Objective: To report our observations on efficacy, adverse events and factors contributing to mortality related with ET performed for the treatment of neonatal hyperbilirubinemia at a tertiary-care centre.

Method: This retrospective study was conducted at the neonatology division of B.P. Koirala Institute of Health Sciences, Nepal. All neonates who required ET for jaundice from January 2013 to December 2014 were included.

Results: Sixty four neonates underwent double volume ET. Predominant causes of hyperbilirubinemia were ABO incompatibility (32.8%), Rh incompatibility (17.2%) and idiopathic (20.3%). There was a mean reduction in serum bilirubin levels to 13.1±3.82 mg/dl in the post-ET and 14.63±3.16 mg/dl in the 6 hour post-ET period. The common adverse events were hypocalcaemia in 50% and thrombocytopenia in 35.9% of neonates. Other events such as hypoglycaemia (17.2%), apnoea (18.8%) and mortality (3.1%) occurred following ET.

Conclusions: ABO incompatibility was the commonest cause for ET. Most of the complications were transient. Mortality rate was 3.1% in this study.

¹Department of Paediatrics, Neonatology Division, B. P. Koirala Institute of Health Sciences, Nepal
*Correspondence: piushkanodia@yahoo.com

(Received on 18 January 2016: Accepted after revision on 17 March 2016)

The authors declare that there are no conflicts of interest

Personal funding was used for this project.

Open Access Article published under the Creative Commons Attribution CC-BY License.

DOI: http://dx.doi.org/10.4038/sljch.v45i4.8061

(Key words: Exchange transfusion, neonatal hyperbilirubinemia, adverse events)

Introduction

Neonatal hyperbilirubinemia is a common cause of admission to the neonatal intensive care unit (NICU)¹. About 50% of term and 80% of preterm babies develop jaundice during the neonatal period² but only 0.02-0.16% develop extreme hyperbilirubinemia³. Breast milk jaundice, ABO incompatibility, Rh incompatibility, Glucose-6-phosphate deficiency (G-6-PD), East Asian ethnicity and cephalhaematoma are conditions associated with severe jaundice⁴. The serum bilirubin level varies with birth weight, gestational age, chronological age and internal milieu of the body. When total serum bilirubin level exceeds a critical limit, it crosses the blood brain barrier and results in bilirubin encephalopathy⁵. Treatment is always given to prevent bilirubin encephalopathy by phototherapy or exchange transfusion (ET)⁶. Although ET is considered to be a safe procedure, it is not risk free, and mortality rates vary from 0.5 to 3.3%⁴,⁷,⁹. Recently, the number of ETs has been significantly reduced due to the availability of highly effective double surface and LED phototherapy and intravenous immunoglobulin G (IVIg) in prevention of isoimmunization / blood group incompatibility¹⁰. ET is sufficient to minimize brain damage, despite the adverse event¹¹.

Objectives

To report our observations on efficacy, adverse events and factors contributing to mortality related with ET performed for the treatment of neonatal hyperbilirubinemia at a tertiary-care centre.

Method

This retrospective study was conducted at the Neonatology Division of B.P. Koirala Institute of Health Sciences (BPKIHS), Nepal. All neonates who required ET from January 2013 to December 2014 were included. The criteria for ET for the management of hyperbilirubinemia were followed as per American Academy of Paediatrics 2004 guidelines¹². Cases of ET for conditions other than jaundice were excluded from the study. The study
was approved by the Institute Ethical Review Board. Detailed baseline characteristics and clinical findings were recorded in a pre-designed proforma. Investigations such as blood glucose, total and indirect serum bilirubin (SB), ionized calcium, haematocrit, haemoglobin, total and differential leucocyte counts, platelet counts and peripheral blood smear, reticulocyte count and direct Coombs test were performed. ABO and Rh blood grouping of both baby and mother were done. Rh disease was defined as jaundice in Rh positive newborns born to Rh negative mothers with elevated antibody titre to the Rh antigen and evidence of haemolysis. ABO disease was attributed as a cause of jaundice in newborns with positive direct Coombs test against the A or B antigens from type O mothers. Infant's blood volume was taken as 80 ml/kg and so 160 ml/kg of blood was required for ET, which replaces 87% of the infant's blood volume with new blood. Exchange was done under a servo-controlled radiant warmer with monitoring of vital parameters. Exchanges were done by the push-pull technique with stored whole blood of less than 5 days duration. Umbilical catheter was inserted as far as required to permit free blood exchange. Blood was removed in aliquots tolerated by the infant, which was 5 ml for infants <1,500g, 10 ml for infants 1,500 to 2,500g, 15 ml for infants 2,500 to 3,500g, and 20 ml for infants >3,500g. If jaundice was the only problem and the baby was active and taking feeds adequately, the baby was considered as a healthy newborn, as opposed to sick neonates who had ongoing illnesses such as birth asphyxia, meconium aspiration syndrome or respiratory distress syndrome that required treatment prior to or at the same time as ET. The adverse events which occurred during and within 3 days of the procedure were observed and managed accordingly. The catheter was removed after the procedure. In sick neonates, supportive treatment in the form of intravenous fluids, oxygen inhalation and empiric antibiotics (ampicillin + amikacin) were given. The antibiotics were changed after culture report as per antimicrobial sensitivity pattern. Biochemical abnormalities such as hypoglycaemia and hypocalcaemia were corrected before doing the ET. However, no intermittent infusions of calcium were given during the procedure as per our NICU protocol. IVIg was not used in any neonate with Rh isoimmunization because of high cost and non-affordability by the parents. Data were analysed using the SPSS version 20.0. Chi-square and Fisher Exact tests were applied to compare the data of proportions and Student’s t-test was used for quantitative variables. A ‘p value less than 0.05 was considered as statistically significant.

**Results**

ET was performed in 64 neonates. Basic characteristics of the study subjects are shown in Table 1.

| Characteristics | Gestational age | P value |
|-----------------|-----------------|---------|
|                 | 37 weeks or > (n=48) | < 37 weeks (n=16) |
| Body weight (Kg) (mean ± SD) | 3.01±0.47 | 1.587±0.47 | <.001 |
| Age at ET (days) (mean ± SD) | 3.67±2.24 | 4.25±1.39 | 0.226 |
| Gender | Male | 31 (64.6%) | 08 (50.0%) | 0.300 |
| Female | 17 (35.4%) | 08 (50.0%) | |
| Race | Mongolian | 24 (50.0%) | 08 (50.0%) | 1.000 |
| Non-Mongolian | 24 (50.0%) | 08 (50.0%) | |
| Place of delivery | Inborn | 27 (56.2%) | 05 (31.2%) | 0.083 |
| Outborn | 21 (43.8%) | 11 (68.8%) | |
| Mode of delivery | SVD | 30 (62.5%) | 14 (87.5%) | 0.62 |
| LSCS | 18 (37.5%) | 02 (12.5%) | |

SVD: Spontaneous vaginal delivery; LSCS: Lower segment caesarean section; SD: Standard deviation

There were 16 preterm and 48 term neonates. Term neonates had significantly higher mean body weight than preterm neonates (p<0.001). Other parameters such as age at exchange transfusion, gender, race and place of delivery were comparable between preterm and term neonates.

Causes of hyperbilirubinaemia included ABO incompatibility (32.8%), Rh incompatibility (17.2%) G6PD deficiency (1.6%) and idiopathic (20.3%). ET was done once in 62 (96.9%) and twice in 2 (3.1%). Mean serum bilirubin levels were 13.1±3.82 mg/dl post ET and 14.63±3.16 mg/dl 6 hour post-ET period. The mean serum bilirubin levels in study subjects are presented in Table 2.
Table 2: Serum bilirubin levels (mg/dl) in study subjects (mean ± SD)

| Group                        | Gestational age | P value |
|------------------------------|-----------------|---------|
|                              | >37 weeks (n=48) | <37 weeks (n=16) |
| Pre Exchange Transfusion     | 24.12±4.01      | 22.55±2.45     | 0.70   |
| Post Exchange Transfusion    | 13.51±3.93      | 11.84±3.26     | 0.102  |
| 6 hours post Exchange Transfusion | 14.91±3.36    | 13.8±2.35      | 0.154  |

Bilirubin levels declined in post-ET and 6 hour post-ET period in comparison to pre-ET values. The term neonates had higher levels of mean SB at all stages (pre-ET, post-ET & 6 hour post-ET) when compared with preterm but this was not statistically significant. The neonates had more than one adverse event and thus 70 adverse events occurred in 64 babies during three days following ET, as shown in Table 3.

Table 3: Adverse events following 3 days of ET

| Adverse event | Complication |
|---------------|--------------|
| Hypocalcaemia | 32 (50.0%)   |
| Thrombocytopenia | 23 (35.9%) |
| Apnoea        | 12 (18.8%)   |
| Hypoglycaemia | 11 (17.2%)   |
| Death         | 02 (03.1%)   |
| Total         | 70           |

Discussion
Prevention of bilirubin encephalopathy is essential and ET is an emergency procedure. In the present study the mean age for ET was 3.7 days and 4.3 days in term and preterm newborns respectively. At BPKIHS newborns come from far off and there are late referrals from peripheral health centres. The common causes of hyperbilirubinaemia were ABO incompatibility (33%), idiopathic (20%) and Rh incompatibility (17%). Steiner et al.10 and Behjata et al.11 found ABO incompatibility in 28% and 52% respectively. However, Behjata et al. also reported Rh incompatibility in 12%. Idiopathic aetiology was the second common cause because we are unable to find any attributable cause in neonates with indirect hyperbilirubinaemia. In different studies idiopathic aetiology varied from 13.9% to 36.4%.13-15 In our study ET was performed once in 97% of neonates and more than once in 3% of cases. Multiple ET was also reported by other workers. The mean SB level in post ET (13.1±3.82) and 6 hour post-ET (14.63±3.16) samples showed a decrease from the pre-ET value but this was not statistically significant. Further, there was a rise in the SB level in the 6 hour post-ET period despite continued phototherapy. Thus, ET removes about 60% of bilirubin from plasma, resulting in a clearance of 30 to 40% of bilirubin17. Following 3 days of ET, hypocalcaemia (50%) and thrombocytopenia (35.9%) were the major adverse events. In our study the high incidence of hypocalcaemia was because we did not use prophylactic calcium during the procedure unless it became symptomatic. Whilst 0.5-1.0 ml of 10% intravenous calcium gluconate, given after each 100 ml of exchange blood, may reduce incidence of hypocalcaemia18, its use is controversial. Thrombocytopenia (36%) was another major adverse event. Besides ET, phototherapy can also cause thrombocytopenia. The other events were hypoglycaemia, respiratory distress, apnoea and cardio-respiratory arrest posing additional problems, which require close monitoring during procedure. Two neonates (3%) died within 24 hours of ET in contrast with other studies which have low mortality rates (0.5-2.8%)19,20. Newborns undergoing ET need close monitoring and prompt treatment for adverse events.

Conclusions
In our study ABO incompatibility was the commonest identified cause of ET. Adverse events remain common after ET. Most complications were transient. Mortality rate was 3% in this study.

References

1. Maisels MJ, Kring E. Length of stay, jaundice, and hospital readmission. Pediatrics 1998; 101(6):995-8. http://dx.doi.org/10.1542/peds.101.6.995

2. Jardine LA, Woodgate P. Neonatal jaundice. American Family Physician 2012; 85(8):824-5.

3. Bhutani VK, Johnson LH, Keren R. Diagnosis and management of hyperbilirubinaemia in the term neonate: for a safer first week. Pediatric Clinics of North America 2004; 51:843–61. http://dx.doi.org/10.1016/j.pcl.2004.03.011 PMid: 15275978

4. Ip S, Chung M, Kulig J, O’Brien R, Sege R, Glicken S et al. An evidence-based review of important issues concerning neonatal hyperbilirubinaemia. Pediatrics 2004; 114(1): 130-53. http://dx.doi.org/10.1542/peds.114.1.e130

5. Brown AK, Danus K, Kim MH et al. Factors relating to readmission of term and near-term neonates in the first two weeks of life. Early Discharge Survey Group of the Health Professional...
Advisory Board of the Greater New York Chapter of the March of Dimes. *Journal of Perinatal Medicine* 1999; 27(4):263-75. http://dx.doi.org/10.1515/JPM.1999.037 PMid: 10560077

6. Smitherman H, Stark AR, Bhutani VK. Early recognition of neonatal hyperbilirubinaemia and its emergent management. *Seminars in Fetal and Neonatal Medicine* 2006; 11(3): 214–24. http://dx.doi.org/10.1016/j.siny.2006.02.002 PMid: 16603425

7. Bowman J. The management of haemolytic disease in the fetus and newborn. *Seminars in Perinatology* 1997; 21(1): 39-44. http://dx.doi.org/10.1016/S0146-0005(97)80018-3

8. Philip AG. The rise and fall of exchange transfusion. *Neo Reviews* 2003; 4: 169-74. http://dx.doi.org/10.1542/neo.4-7-e169

9. Boggs TR Jr, Westphal MC Jr. Mortality of exchange transfusion. *Pediatrics* 1960; 26: 745-55.

10. Steiner LA, Bizzarro MJ, Ehrenkranz RA, Gallagher PG. A decline in the frequency of neonatal exchange transfusions and its effect on exchange related morbidity and mortality. *Pediatrics* 2007; 120(1):27–32. http://dx.doi.org/10.1542/peds.2006-2910 PMid: 17606558

11. Behjata S, Sagheb S, Aryasepehr S, Yaghmai B. Adverse events associated with neonatal exchange transfusion for hyperbilirubinemia. *Indian Journal of Pediatrics* 2009; 76:83-5. http://dx.doi.org/10.1007/s12098-009-0033-1 PMid: 19391007

12. American Academy of Pediatrics Practice Guidelines. Subcommittee on hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 weeks or more of gestation. *Pediatrics* 2004; 114:297–316. http://dx.doi.org/10.1542/peds.114.1.297 PMid: 15231951

13. Davutoğlu M, Garipardıç M, Güler E et al. The etiology of severe neonatal hyperbilirubinemia and complications of exchange transfusion. *Turkish Journal of Pediatrics* 2010; 52: 163-6. PMid: 20560252

14. Bhat AW, Churoo BA, Iqbal Q et al. Complication of exchange transfusion at a tertiary care hospital. *Current Pediatric Research* 2011; 15(2):97-9.

15. Sakha SH, Gharehbaghi MM. Exchange transfusion in severe hyperbilirubinemia: an experience in northwest Iran. *Turkish Journal of Pediatrics* 2010; 52:367-71.

16. Badiee Z. Exchange transfusion in neonatal hyperbilirubinemia: experience in Isfahan, Iran. *Singapore Medical Journal* 2007; 48(5):421-3. PMid: 17453099

17. Maissels MJ. Neonatal hyperbilirubinemia. In: Care of the high-risk neonate. 5th edition. W.B. Sounders. Philadelphia. 2001. pp 363-64. http://dx.doi.org/10.1016/B978-0-7216-7729-3.50017-2

18. Nelson N, Finnström O. Blood exchange transfusions in newborns, the effect on serum ionized calcium. *Early Human Development* 1988; 18(2-3):157-64.

19. Patra K, Storfer-Isser A, Siner B et al. Adverse events associated with neonatal exchange transfusion in the 1990s. *Journal of Pediatrics* 2004; 144:626-31. http://dx.doi.org/10.1016/j.jpeds.2004.01.054 PMid: 15126997

20. Choudhury HR, Hasan MA, Yasmin F. Outcome of neonatal hyperbilirubinemia in a tertiary care hospital in Bangladesh. *Malays Journal of Medical Science* 2010; 17:40-44.